Recombinant lipase - Mayoly-Spindler/AzurRx BioPharma

Drug Profile

Recombinant lipase - Mayoly-Spindler/AzurRx BioPharma

Alternative Names: Lipase - Mayoly-Spindler/Protea Biosciences; MS-1819; MS1819 recombinant lipase

Latest Information Update: 24 Nov 2016

Price : $50

At a glance

  • Originator Mayoly-Spindler
  • Developer AzurRx BioPharma; Mayoly-Spindler
  • Class Carboxylic ester hydrolases
  • Mechanism of Action Lipase replacements; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Exocrine pancreatic insufficiency; Pancreatitis

Most Recent Events

  • 17 Nov 2016 Phase-II clinical trials in Exocrine pancreatic insufficiency in Australia (PO)
  • 17 Nov 2016 Phase-II clinical trials in Exocrine pancreatic insufficiency in New Zealand (PO)
  • 27 Jul 2016 AzurRx plans a phase IIa trial for Exocrine pancreatic insufficiency in Australia and New Zealand (PO, Capsule) (ACTRN12616000962437p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top